{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-000342","form_type":"8-K","ticker":"ZIVO","cik":"0001101026","company_name":"Zivo Bioscience, Inc.","filed_at":"2022-01-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.418258+00:00","generated_at":"2026-06-27T18:50:50.290243+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ZIVO Bioscience terminates CEO Andrew Dahl; Chairman John Payne named President and CEO","bullets":["Andrew A. Dahl terminated as President and CEO on January 4, 2022.","John B. Payne, previously Chairman, appointed President and CEO effective January 7, 2022.","Payne founded Compassion-First Pet Hospitals; served as President and CEO until 2020.","Payne removed from Compensation and Audit Committees; Christopher Maggiore appointed.","Company highlights 2021 progress including Nasdaq uplisting; expects seamless transition."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-000342","json":"https://secwatch.observer/filing/0001654954-22-000342.json","markdown":"https://secwatch.observer/filing/0001654954-22-000342.md","text":"https://secwatch.observer/filing/0001654954-22-000342.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1101026/000165495422000342/0001654954-22-000342-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1101026/000165495422000342/zivo_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T18:50:50.290243+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e2228a54c","claim":"John B. Payne was appointed as President and Chief Executive Officer at Zivo Bioscience, Inc..","evidence_excerpt":"Effective as of January 7, 2022, the Board of the Company appointed Mr. John B. Payne as the Company’s President and Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495422000342/0001654954-22-000342-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"80fdfc6036","claim":"Andrew A. Dahl was terminated as President and Chief Executive Officer at Zivo Bioscience, Inc..","evidence_excerpt":"On January 4, 2022, Zivo Bioscience, Inc. (the “Company” ) terminated the employment of Andrew A. Dahl, the President and Chief Executive Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495422000342/0001654954-22-000342-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}